Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells

[1]  Jiaolin Bao,et al.  The Anticancer Properties of Salvia Miltiorrhiza Bunge (Danshen): A Systematic Review , 2014, Medicinal research reviews.

[2]  Jiri Polivka,et al.  Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. , 2014, Pharmacology & therapeutics.

[3]  F. Liu,et al.  Targeting mTOR: evaluating the therapeutic potential of resveratrol for cancer treatment. , 2013, Anti-cancer agents in medicinal chemistry.

[4]  J. Pelling,et al.  Targeting the PI3K/Akt/mTOR axis by apigenin for cancer prevention. , 2013, Anti-cancer agents in medicinal chemistry.

[5]  D. Hardie,et al.  AMPK: A Target for Drugs and Natural Products With Effects on Both Diabetes and Cancer , 2013, Diabetes.

[6]  G. Mills,et al.  AMPK: a contextual oncogene or tumor suppressor? , 2013, Cancer research.

[7]  F. Berrino,et al.  Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects , 2013, Oncogene.

[8]  Xianglin Shi,et al.  Quercetin Inhibits Angiogenesis Mediated Human Prostate Tumor Growth by Targeting VEGFR- 2 Regulated AKT/mTOR/P70S6K Signaling Pathways , 2012, PloS one.

[9]  R. Coleman,et al.  The PI3K/AKT/mTOR Pathway as a Therapeutic Target in Endometrial Cancer , 2012, Clinical Cancer Research.

[10]  Y. Odaka,et al.  Cryptotanshinone Activates p38/JNK and Inhibits Erk1/2 Leading to Caspase-Independent Cell Death in Tumor Cells , 2012, Cancer Prevention Research.

[11]  D. Sabatini,et al.  mTOR Signaling in Growth Control and Disease , 2012, Cell.

[12]  N. Gough.  Focus Issue: TOR Signaling, a Tale of Two Complexes , 2012, Science Signaling.

[13]  D. Hardie,et al.  AMPK: a nutrient and energy sensor that maintains energy homeostasis , 2012, Nature Reviews Molecular Cell Biology.

[14]  K. Inoki,et al.  AMPK and mTOR in cellular energy homeostasis and drug targets. , 2012, Annual review of pharmacology and toxicology.

[15]  Derek LeRoith,et al.  Diabetes, cancer, and metformin: connections of metabolism and cell proliferation , 2011, Annals of the New York Academy of Sciences.

[16]  J. Tamburini,et al.  LKB1/AMPK/mTOR signaling pathway in hematological malignancies: From metabolism to cancer cell biology , 2011, Cell cycle.

[17]  P. Schumacker,et al.  Hypoxia Triggers AMPK Activation through Reactive Oxygen Species-Mediated Activation of Calcium Release-Activated Calcium Channels , 2011, Molecular and Cellular Biology.

[18]  M. Peppelenbosch,et al.  The long and winding road to rational treatment of cancer associated with LKB1/AMPK/TSC/mTORC1 signaling , 2011, Oncogene.

[19]  B. Hennessy,et al.  Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. , 2011, The Journal of clinical investigation.

[20]  R. Copeland,et al.  Epigallocatechin gallate (EGCG), a major component of green tea, is a dual phosphoinositide-3-kinase/mTOR inhibitor. , 2011, Biochemical and biophysical research communications.

[21]  J. Tabernero,et al.  Pushing the Envelope in the mTOR Pathway: The Second Generation of Inhibitors , 2011, Molecular Cancer Therapeutics.

[22]  F. Liu,et al.  Resveratrol Inhibits mTOR Signaling by Promoting the Interaction between mTOR and DEPTOR* , 2010, The Journal of Biological Chemistry.

[23]  Yan Luo,et al.  Updates of mTOR inhibitors. , 2010, Anti-cancer agents in medicinal chemistry.

[24]  Xiuzhen Han,et al.  Cryptotanshinone Inhibits Cancer Cell Proliferation by Suppressing Mammalian Target of Rapamycin–Mediated Cyclin D1 Expression and Rb Phosphorylation , 2010, Cancer Prevention Research.

[25]  J. Dancey.  mTOR signaling and drug development in cancer , 2010, Nature Reviews Clinical Oncology.

[26]  Baoshan Xu,et al.  Hydrogen peroxide inhibits mTOR signaling by activation of AMPKα leading to apoptosis of neuronal cells , 2010, Laboratory Investigation.

[27]  B. Viollet,et al.  Hypoxic activation of AMPK is dependent on mitochondrial ROS but independent of an increase in AMP/ATP ratio. , 2009, Free radical biology & medicine.

[28]  G. Zhou,et al.  AMPK activators – potential therapeutics for metabolic and other diseases , 2009, Acta physiologica.

[29]  R. Memmott,et al.  Akt-dependent and -independent mechanisms of mTOR regulation in cancer. , 2009, Cellular signalling.

[30]  N. Webster,et al.  Curcumin disrupts the Mammalian target of rapamycin-raptor complex. , 2009, Cancer research.

[31]  B. Turk,et al.  AMPK phosphorylation of raptor mediates a metabolic checkpoint. , 2008, Molecular cell.

[32]  David M Sabatini,et al.  Defining the role of mTOR in cancer. , 2007, Cancer cell.

[33]  J. Ha,et al.  Antidiabetes and Antiobesity Effect of Cryptotanshinone via Activation of AMP-Activated Protein Kinase , 2007, Molecular Pharmacology.

[34]  J. Blenis,et al.  Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways , 2006, Oncogene.

[35]  K. Guan,et al.  Upstream of the mammalian target of rapamycin: do all roads pass through mTOR? , 2006, Oncogene.

[36]  Ming You,et al.  TSC2 Integrates Wnt and Energy Signals via a Coordinated Phosphorylation by AMPK and GSK3 to Regulate Cell Growth , 2006, Cell.

[37]  Shile Huang,et al.  Curcumin inhibits the mammalian target of rapamycin‐mediated signaling pathways in cancer cells , 2006, International journal of cancer.

[38]  M. Hall,et al.  TOR Signaling in Growth and Metabolism , 2006, Cell.

[39]  Zhong Zuo,et al.  Danshen: An Overview of Its Chemistry, Pharmacology, Pharmacokinetics, and Clinical Use , 2005, Journal of clinical pharmacology.

[40]  D. Guertin,et al.  Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.

[41]  K. Inoki,et al.  TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival , 2003, Cell.

[42]  J. Crespo,et al.  Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. , 2002, Molecular cell.

[43]  J. Avruch,et al.  Raptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR Action , 2002, Cell.

[44]  Shile Huang,et al.  Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. , 2002, Current opinion in investigational drugs.

[45]  Christine C. Hudson,et al.  A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. , 2000, Cancer research.

[46]  A. Brüning,et al.  Proteasome inhibition by quercetin triggers macroautophagy and blocks mTOR activity , 2011, Histochemistry and Cell Biology.

[47]  K. Inoki,et al.  TSC2: filling the GAP in the mTOR signaling pathway. , 2004, Trends in biochemical sciences.